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The impact of the dose time ratio on the outcomes
in postoperative radiation therapy for non small cell lung cancer
Jolanta Szelachowska1, Micha∏ Jeleƒ2, Jan Kornafel1
I n t r o d u c t i o n.  The aim of the study was to analyse the results of irradiation and the prognostic factors related to clinical,
pathological and therapeutic characteristics observed in patients with non-small cell lung cancer.
M a t e r i a l  a n d  m e t h o d.  We analysed the cases of 64 patients with primary non-small cell lung cancer treated between the
years 1994-2000, who were operated on in the Lower Silesian Lung Disease Center and underwent postoperative irradiation
at the Lower Silesian Oncology Center. Dose fractionation was 2 Gy or 2.66 Gy per day, with five fractions per week; total dose
was 39.9 to 64 Gy. The results were analysed statistically. We examined the correlations between the following parameters and
their influence on survival and disease-free survival – gender, age, type of operation, radicality of operation, pTNM, histologic
subtype, grade of histologic malignancy, number of chemotherapy cycles, total dose of radiotherapy, dose intensity, fractionation
dilution and the dose time ratio.
R e s u l t s.  Only the grade of histologic malignancy and parameters connected with the intensity of radiotherapy influenced
patient survival. Local Disease Free Survival (LDFS) and Disease Free Survival (DFS) were statistically significantly shorter
among patients with Dose Intensity (DI) <1.35 and Local Disease Free Survival (LDFS) – among patients with Fractionation
Dilution (FD) >1.47. The Dose Time Ratio (DTR) on Local Disease Free Survival (LDFS) and Disease Free Survival (DFS)
exhibited the strongest statistical power, but there was no influence on Overall Survival (OS).
C o n c l u s i o n.  Interruptions during postoperative radiotherapy are detrimental for disease-free survival and survival free of
locoregional relapse in patients with NSCLC.
Wp∏yw wspó∏czynnika dawka – czas na wynik pooperacyjnej radioterapii
u chorych na niedrobnokomórkowego raka p∏uca
C e l.  Celem pracy by∏a analiza wp∏ywu wybranych czynników klinicznych i patologicznych na prze˝ycie chorych na
niedrobnokomórkowego raka p∏uca, leczonych z zastosowaniem pooperacyjnej radioterapii.
M a t e r i a ∏  i m e t o d a.  Materia∏ do badania pochodzi∏ od 64 pacjentów z rozpoznaniem niedrobnokomórkowego raka
p∏uca, leczonych operacyjnie w DolnoÊlàskim Centrum Gruêlicy i Chorób P∏uc w latach 1996-2000, a nast´pnie poddanych
uzupe∏niajàcej radioterapii w DolnoÊlàskim Centrum Onkologii. W trakcie radioterapii stosowane by∏y dawki frakcyjne 2 Gy
i 2,66 Gy dziennie, przez 5 dni w tygodniu do dawki ca∏kowitej mi´dzy 39,9 Gy a 64 Gy. Analizie statystycznej zosta∏y
poddane korelacje mi´dzy nast´pujàcymi parametrami – p∏eç, wiek, typ operacji, stopieƒ radykalnoÊci operacji, stopieƒ
zaawansowania choroby pTNM, podtyp histologiczny raka, stopieƒ z∏oÊliwoÊci histologicznej nowotworu, liczba cykli
chemioterapii, dawka ca∏kowita radioterapii, Wskaênik IntensywnoÊci Dawki, Wskaênik PowtarzalnoÊci Frakcji i Wspó∏czynnik
Dawka-Czas, oraz ich wp∏yw na prze˝ycie pacjentów.
W y n i k i.  SpoÊród badanych czynników jedynie stopieƒ z∏oÊliwoÊci histologicznej guza i parametry zwiàzane z intensywnoÊcià
radioterapii mia∏y wp∏yw na prze˝ycie pacjentów. StwierdziliÊmy istotne statystycznie skrócenie czasu Prze˝ycia Wolnego od
Nawrotu Miejscowego Choroby (LDFS) i Prze˝ycia Wolnego od Nawrotu Choroby (DFS) wÊród pacjentów ze Wskaênikiem
IntensywnoÊci Dawki (DI) <1,35, oraz skrócenie Czasu Prze˝ycia Wolnego od Nawrotu Miejscowego Choroby (LDFS)
wÊród pacjentów o Wskaêniku PowtarzalnoÊci Frakcji (FD) >1,47. Wspó∏czynnik Dawka-Czas wykazywa∏ silny statystycznie
wp∏yw na czas Prze˝ycia Wolnego od Nawrotu Miejscowego Choroby (LDFS) i Prze˝ycia Wolnego od Nawrotu Choroby
(DFS), jednak˝e nie mia∏ wp∏ywu na Prze˝ycie Ca∏kowite (OS) pacjentów.
W n i o s k i.  Wyniki te potwierdzajà negatywny wp∏yw przerw w trakcie pooperacyjnej radioterapii na prze˝ycie wolne od
choroby u pacjentów z rozpoznaniem niedrobnokomórkowego raka p∏uca.
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Introduction
Lung cancer was the most common cause of cancer
deaths in 1996 in the region of Lower Silesia in Poland. It
accounted for 10.8% of all malignancies among women,
second only to breast cancer. Among men it was the most
common type of cancer – 28.1% of all cancer morbidities.
Five-year survival among men reached 7%, and among
women – 12.1% [1]. Surgery remains the basic treatment
modality and offers the best chance to cure patients with
NSCLC. However, less than 1/3 of these patients are
suitable for surgery and the results of treatment are poor,
because even if radical surgery is possible still a majority
of patients are not free of the disease. Supplemental
therapy remains a necessity. However, the efficiency of
postoperative radiotherapy is controversial [2-13]. Some
authors suggest that postoperative radiotherapy may not
only decrease the rate of local recurrences but also
positively influence the survival of patients with resected
N2 disease [2, 3, 7, 10, 11]. In case of incomplete
resection, postoperative radiotherapy has a positive
impact on survival [4, 9]. Despite the lack of obvious
evidence, most experts continue to recommend post-
operative irradiation for patients with NSCLC in the N2
setting and after incomplete resection (defined as the
presence of microscopic or macroscopic residual disease
or disease in the highest resected paratracheal lymph
node).
Material and methods
We have analysed the cases of 64 patients with primary non-
small cell lung cancer, who were operated on in Lower Silesian
Lung Disease Center and postoperatively underwent radiation
therapy at the Lower Silesian Oncology Center. The study
covered the years from 1996 until 2000. Histopathologic types of
primary tumours and treatment modalities are presented in
Table I. TNM classification of the patients and the radicality of
the operation are presented in Table II. All patients were
irradiated postoperatively. The time from operation to
radiotherapy varied between 3 and 29 weeks (the difference
was brought on by the administration of postoperative chemo-
therapy). Fractionation was 2 Gy or 2.66 Gy per day, with five
fractions per week; total dose was 39.9 to 64 Gy. Postoperative
chemotherapy was administered to 35 patients and was delivered
before radiotherapy. The most common chemotherapy regimens
were: cisplatin with etoposide, and mitomycin with ifosfamid
and cisplatin. Because of the two different fractionation
schedules we re-calculated the Normalized Total Dose (NTD)
using the linear – quadratic formula; where TD is the total
physical dose delivered by fractionation of d Gy per day, and a/b
characterises the tissue under consideration (35Gy for lung
cancer) [14, 15].
NTD = TD (a/b + d)/(a/b + 2.0)
Furthermore, because of interruptions in the course of
radiotherapy caused by machine breakdowns, we also took into
consideration loss of part of the dose to defray repopulation
[16]. We calculated the Normalised Total Dose with time
correction (NTD-T) assuming a loss of 0.6 Gy per each day of
the break. These calculations were used in case of breaks during
treatment if the overall time of radiotherapy was longer than 28
days. The next parameters which characterised radiotherapy
were the Dose Intensity Factor (Total Dose/Overall Time of
Radiotherapy), the Fractionation Dilution Factor (Overall Time
of Radiotherapy/Number of Fractions) and the Dose Time Ratio
(Dose Intensity Factor/ Fractionation Dilution Factor) which
defines the degree of interdependency between the first two
[17, 18].
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Table I. The histopathologic types of primary tumours and the treatment modalities
No of patients Histopathology In total
squamous ca. adenoca. large cell ca.
24 23 17 64
Type of operation wegde resection 0 1 0 1
lobectomy 10 17 10 37
bilobectomy 2 2 0 4
pulmonectomy 12 3 7 22
No of chemotherapy cycles 0 14 9 5 28
1-2 2 3 7 12
3 5 9 5 19
4-6 3 2 0 5
fractionation of postoperative radiotherapy df=2Gy 21 14 13 48
df=2.66Gy 3 9 4 16
Table II. TNM classification of patients and surgical radicality
Radicality of the operation pTNM stages
I IIA IIB III
radical operation 0 0 2 0
uncertain radicality 0 0 5 11
incomplete resection 5 4 10 27
Overall cancer-specific survival was defined as the period
from the date of the operation to the date of cancer-death. An
observation was made at the last follow-up to determine whether
the patient was alive or had died of a cause other than NSCLC.
Disease Free Survival was defined similarly. Kaplan-Meier
curves were calculated for each variable. The log-rank test and
Cox’s proportional hazards model were used to examine the
relationship between cancer-specific survival, disease-free
survival and various potential prognostic factors. The level of
significance was set at p<0.05. The association of all markers
with clinicopathological parameters was evaluated using the
Chi-square Test. Statistical analysis was performed using
STATISTICA software, ver. 6.
Results
We examined the association between the following
parameters and their influence on overall survival and
disease-free survival – gender, age, type of operation,
radicality of operation, pTNM, histologic subtype, grade
of histologic malignancy, number of chemotherapy cycles,
total dose of radiotherapy, dose intensity, fractionation
dilution and the dose time ratio.
Table III shows mean DFS and OS. Only the grade
of histologic malignancy (Figure 1) and parameters
connected with the intensity of radiotherapy achieved
statistical significance as factors affecting patient survival.
There was no correlation between the time lapse between
surgery and radiotherapy, or between overall duration
of radiotherapy and patient survival. Patients were divided
into three groups (according to the level of the Nor-
malised Total Dose): those who received low doses (40.6-
42 Gy), medium doses (46-52 Gy), and high doses (54-60
Gy). There was no difference in Local Progression-Free
Survival (LPFS), Disease Free Survival (DFS), or Overall
Survival (OS) between these three groups. Similarly,
patients were categorised according to the level of
Normalised Total Dose with time correction, which also
failed to influence patient survival.
According to the Dose Intensity Factor (DI) patients
were divided into two groups:
0 – 27 patients with DI below 1.35
1 – 37 patients with DI above 1.35.
Patients with DI higher than 1.35 had statistically
longer DFS (Figure 2) and LPFS (Figure3). There was no
difference in OS between these groups.
According to the Fractionation Dilution Factor (FD)
patients were divided into two groups:
0 – 32 patients with FD above 1.47
1 – 32 patients with FD below 1.47.
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Table III.  Disease Free Survival (DFS) and Overall Survival (OS) in weeks from the date of the operation
Women Men Medium Minimum Maksimum Standard deviation
(weeks) (weeks) (weeks)
DFS OS DFS OS DFS OS DFS OS
Healthy 6 14 182 182 104 104 285 285 53.0 53
Distant progression 6 13 59 105 10 21 155 223 31.4 51
Loco-regional progression 2 7 95 129 44 62 175 209 52.4 54
Loco-regional progression and distant progression 1 5 68 98 27 56 143 153 42.0 38
Another cancer 0 2 96 141 54 92 138 190 59.3 69
Death without cancer progression 0 8 85 85 32 32 213 213 65.0 65
In total 15 49 107 130 10 21 285 285 69.5 63
Figure 1. Overall survival of the patients according to the grade of
cancer malignancy
Figure 2. Disease free survival of patients according to the level of the
Dose Intensity Factor (DI) (p = 0.047)
There was a statistically important difference in
LPFS between patients with FD <1.47 and FD > 1.47
(Figure 4). There was no difference in DFS and OS
between these groups of patients.
The Dose Time Ratio (DTR) categorised patients
into two groups: one group of 22 patients with DTR
lower than 0.95, and another group of 42 patients with
DTR higher or equal to 0.95. LPFS (Figure 5) and DFS
(Figure 6) were statistically significantly shorter among
patients with DTR <0.95. There was no difference in OS
between these two groups.
Discussion
The aim of this study was to analyse the efficiency of
postoperative radiotherapy in patients treated for non-
small lung cancer in one institution.
The probability of sterilizing a tumour after
radiotherapy is influenced by a number of factors, the
most important among them being tumour volume,
tumour kinetics, intrinsic cellular radiosensitivity, dose
and fractionation of radiotherapy, and overall time of
radiotherapy. The influence of all these parameters is
directly related.
We observed no influence of the level of the
Normalised Total Dose nor of the Normalised Total Dose
with Time correction on patient survival in the analysed
group. However, we suppose that these results may be, to
some extent, erroneous, because factor a/b considered in
these calculations has not been estimated precisely and
because the dose equivalent of repopulation was based on
records obtained also from head and neck cancer patients.
Therefore in order to compare the results of different
fractionations of radiotherapy (different doses per
fraction and interruptions during treatment), we used
Maciejewski’s conception of simple factors – Dose
Intensity, Fractionation Dilution and Dose Time Ratio
[17, 18].
We observed significantly shorter LDFS and DFS
in patients with DI <1.35 and shorter LDFS in
patients with FD >1.47. DTR on LDFS and DFS
exhibited the strongest statistical power, but failed to
influence OS.
If the dose per fraction (d) is not altered in the
course of radiotherapy, we can describe DTR as:
DTR =d/(FD)2
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Figure 4. Local progression-free survival of patients according to the
level of the Fractionation Dilution Factor (FD) (p = 0.012)
Figure 5. Local progression-free survival of patients according to the
level of the Dose Time Ratio (DTR) (p = 0.0012)
Figure 3. Local progression-free survival of patients according to the
level of the Dose Intensity Factor (DI) (p = 0.013)
Figure 6. Disease free survival of patients according to the level of the
Dose Time Ratio (DTR) (p = 0.028)
Thus DTR decreases when there are breaks in the
course of radiotherapy (increased FD). Decreased DTR
negatively influences DFS and LDFS. Our patients were
administered two different doses per fraction: 2 Gy and
2.66 Gy. Because DTR 0.95 correlated with poorer
survival, in the case of 2 Gy per fraction it corresponded
to FD higher than 1.45 or to interruptions in radiotherapy
lasting at least two days. In the case of 2.66 Gy per
fraction it corresponded to FD higher than 1.67 or a five
day break.
In view of these results one may assume that the
time-table of radiotherapy is more important than the
level of the total dose. However, the negative correlation
between the total dose and the effect of radiotherapy
should be approached cautiously, as we lack credible
calculations of the a/b factor and the dose – equivalent of
repopulation for different histologic subtypes of lung
cancer. The dose – equivalent of repopulation was
estimated from records of head and neck cancers. Even in
the case of this type of cancer, quantitative estimates of
the time factor are problematic and should be used with
caution [19].
The CHART study confirmed the great significance
of the accelerated repopulation of clonogenic tumour
cells during the course of radiotherapy. The outcome
after CHART was better than after conventional
treatment, despite the 6 Gy reduction of the total dose,
but overall treatment time was shortened from six weeks
to 12 days. The conclusion of this study was the suggestion
that repopulation is an important factor to be considered
when planning the management of NSCLC and that the
overall duration of treatment should be kept as short as
possible [20]. Cox and others have been the first to show
that interruptions lasting more than five days during high
– dose (>69.6 Gy) radiation therapy decreased long term
survival in favourable patients with unresectable NSCLC
[21]. The result of this study indicated the exceptional
role of the time factor in the radiotherapy of lung cancer
[22]. A paper by Koukourakis et al. also proves that
prolonged treatment time had a negative impact on
survival [23]. In 2000 Chen et al. observed a statistically
significant decrease of survival among patients whose
overall treatment time was longer than 45 days. They
calculated that overall treatment time prolonged for one
week causes a 9% decrease in the three year Local
Disease Free Survival [24].
Although it seems likely that accelerated tumour
cell repopulation does occur during radiotherapy for
NSCLC, there is lack of sufficient data to estimate it
quantitatively. For this reason, it seems appropriate to
compare the results of radiotherapy using simple factors,
which characterise the intensity of radiotherapy at the
time of its application.
There is a little data in literature concerning the
influence of prolonged time of postoperative radiotherapy
on the survival of NSCLC patients. We have shown that
interruptions during postoperative radiotherapy are
detrimental for disease-free survival and locoregional
relapse-free survival in patients with NSCLC.
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